Endo International plc

  • TickerENDP
  • ISINIE00BJ3V9050
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

ENDO INTERNATIONAL suffers a double requalification, which weighs heavily on its rating, now at Negative.

The independent financial analyst theScreener just downgraded the general evaluation of ENDO INTERNATIONAL (US), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title loses a star(s) and now shows 0 out of 4 stars. Its market behaviour is also negatively reassessed and may be considered as risky. theScreener believes that this double requalification keeps the title under pressure and justifies an overall rating downgrade to Negative. As of the analysis date May 11, 2021, the closing price was USD 5.16 and its target price was estimated at USD 3.99.

MarketLine Department

Purdue Pharma L.P. - Strategy, SWOT and Corporate Finance Report

Summary Purdue Pharma L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Purdue Pharma L.P. (Purdue or 'the company') is a privately-held pharmaceutical company that carries out the research, development, production and marketing of prescription and over-the-counter (OTC) medicines and healthcare products. The company serves healthcare professionals, patients ...

MarketLine Department

United Therapeutics Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's United Therapeutics Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by United Therapeutics Corporation since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain it...

MarketLine Department

Purdue Pharma L.P. - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Purdue Pharma L.P. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Purdue Pharma L.P. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. ...

MarketLine Department

Mylan NV - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Mylan NV Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Mylan NV since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlights This...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A number of names in the Communications Sector are showing signs of leadership. (ex. GLUU, TWTR, GOOGL, NYT, and NWSA) • Consumer Discretionary continues to have a number of attractive names technically. (ex. TPR, LGIH, DHI, VSTO, RGR, PENN, SGMS, BYD, BJRI, BKE, EBAY, SIG, HAIN, and ENR ) • A number of Financial Sector names appear to be perking up. (ex. JHG, INTL, EVR, GHL, ARR, and CINF)

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

1 director sold

A director at Endo International Plc sold 55,000 shares at 4.090USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names o...

MarketLine Department

Purdue Pharma L.P. - Strategy, SWOT and Corporate Finance Report

Summary Purdue Pharma L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Purdue Pharma L.P. (Purdue or 'the company') is a privately-held pharmaceutical company that carries out the research, development, production and marketing of prescription and over-the-counter (OTC) medicines and healthcare products. The company serves healthcare professionals, patients ...

MarketLine Department

United Therapeutics Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's United Therapeutics Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by United Therapeutics Corporation since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain it...

MarketLine Department

Purdue Pharma L.P. - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Purdue Pharma L.P. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Purdue Pharma L.P. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. ...

MarketLine Department

Mylan NV - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Mylan NV Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Mylan NV since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlights This...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Valens Research

Valens Credit Weekly Insights - 2018 05 09

Valens Credit Research Team highlighted ideas for CYH, DOOR, and X. They have also provided recent analyses for AL and GOGO, while CYH topped the quantitative outlier report for the week.

Valens Research

Valens Credit Weekly Insights - 2018 05 02

Valens Credit Research Team highlighted ideas for CAR, DNR, and WU. They have also provided recent analyses for RCL and UVV, while CYH topped the quantitative outlier report for the week.

Valens Research

Valens Credit Weekly Insights - 2018 04 25

Valens Credit Research Team highlighted ideas for BZH, MNI, and YRCW. They have also provided recent analyses for AXL and DF, while CYH topped the quantitative outlier report for the week.

Valens Research

Valens Credit Weekly Insights - 2018 04 18

Valens Credit Research Team highlighted ideas for AN, AVP, and UIS. They have also provided recent analyses for SUM and AMKR, while CYH topped the quantitative outlier report for the week.

Valens Research

Valens Credit Weekly Insights - 2018 04 11

Valens Credit Research Team highlighted ideas for AER, CHK, and NFX. They have also provided recent analyses for ENDP and OC, while CYH topped the quantitative outlier report for the week.

ENDO INTERNATIONAL suffers a double requalification, which weighs heavily on its rating, now at Negative.

The independent financial analyst theScreener just downgraded the general evaluation of ENDO INTERNATIONAL (US), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title loses a star(s) and now shows 0 out of 4 stars. Its market behaviour is also negatively reassessed and may be considered as risky. theScreener believes that this double requalification keeps the title under pressure and justifies an overall rating downgrade to Negative. As of the analysis date May 11, 2021, the closing price was USD 5.16 and its target price was estimated at USD 3.99.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch